Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
All SELVA participants who completed the treatment-satisfaction questionnaire reported satisfaction with treatment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palvella Therapeutics (PVLA) announced three posters presenting Phase 3 SELVA findings and a U.S. analysis of diagnosed DSAP patients. At Week 24, all exit-interview participants reported meaningful improvement in at least one symptom of microcystic lymphatic malformations. Among participants completing the 24-week efficacy period, 95% improved on the primary investigator assessment, including 86% rated “Much Improved” or “Very Much Improved”; 98% elected continued treatment.
A 24-participant substudy found mean systemic rapamycin exposure at least 40-fold lower than reported oral sirolimus exposure, with low, stable concentrations over 24 hours. Palvella completed its FDA application submission for QTORIN rapamycin in August 2026. Claims analysis estimated 154,986 U.S. patients diagnosed with disseminated superficial actinic porokeratosis (DSAP) during 2018–2025. Palvella anticipates starting a Phase 2 QTORIN pitavastatin trial in the fourth quarter of 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point95% of SELVA 24-week efficacy-period completers improved on the primary assessment; 86% were “Much Improved” or “Very Much Improved.”
- Moderate pointQTORIN rapamycin FDA application rolling submission was completed in August 2026 for microcystic lymphatic malformations.
- Minor pointAll Week 24 exit-interview participants reported meaningful improvement in at least one microcystic lymphatic malformation symptom.
- Minor pointAll TSQM-9 questionnaire completers reported treatment satisfaction.
- Minor point98% of SELVA 24-week efficacy-period completers elected to continue treatment in the extension period.
3 minor points
- Minor point24-participant substudy found mean systemic exposure at least 40-fold lower than reported oral sirolimus exposure.
- Minor pointSystemic rapamycin concentrations remained low and stable over 24 hours, with exposure consistent across assessed groups.
- Minor point. Forward-looking: it has not happened yet and may not happen.QTORIN pitavastatin Phase 2 trial for DSAP is anticipated to commence in the fourth quarter of 2026.
Negative
- None.
Key Figures
- Treatment extension election
- 98%
- SELVA participants completing the 24-week Efficacy Evaluation Period
- Primary endpoint improvement
- 95%
- Participants completing the 24-week Efficacy Evaluation Period
- Much or very much improved
- 86%
- Participants completing the 24-week Efficacy Evaluation Period; mLM-IGA
- PK substudy participants
- 24 participants
- Maximal-use substudy in microcystic lymphatic malformations
- Systemic rapamycin exposure
- At least 40-fold lower
- QTORIN rapamycin versus reported oral sirolimus exposure
- Systemic exposure observation period
- 24 hours
- Exposure remained low and stable
- Diagnosed U.S. DSAP population
- 154,986 patients
- Estimated diagnosed population during 2018–2025
Historical Context
-
Earlier report said SELVA met its primary and secondary endpoints, contextualizing the interview findings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pharmacokinetic technical
new drug application regulatory
icd-10 diagnosis code medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin
SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours
Comprehensive Real-World Claims Analysis Identifies an Estimated 154,986 Patients Diagnosed With DSAP in the U.S.
WAYNE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced three poster presentations at the 26th Annual Fall Clinical Dermatology Conference. Copies of the posters are available here in the “Publications & Presentations” section of Palvella’s website. The findings are expected to be submitted for publication in peer-reviewed journals.
The presentations highlight findings from patient, caregiver, and clinician interviews conducted as part of the Phase 3 SELVA study evaluating QTORIN™ rapamycin in microcystic lymphatic malformations (microcystic LMs); systemic exposure data from the SELVA maximal-use pharmacokinetic substudy; and a real-world claims analysis estimating the U.S. population diagnosed with disseminated superficial actinic porokeratosis (DSAP).
SELVA Participant Interviews Highlight Clinical Benefits and High Treatment Satisfaction with QTORIN™ Rapamycin for Microcystic LMs
The poster, titled “Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel
At Week 24, all exit-interview participants reported improvement in at least one symptom of microcystic LMs, most commonly bleeding/leaking and color, and described these improvements as meaningful. Patient, caregiver, and clinician interviews revealed consistent improvements in key manifestations of microcystic LMs. All participants who completed the TSQM-9 reported treatment satisfaction, and
These findings were consistent with the positive clinical efficacy results from the Phase 3 SELVA study. Among participants who completed the 24-week Efficacy Evaluation Period,
SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours
The poster, titled “Systemic Pharmacokinetics of Investigational Sirolimus Topical Gel
In a maximal-use pharmacokinetic substudy involving 24 participants with microcystic LMs, mean systemic rapamycin exposure with QTORIN™ rapamycin was at least 40-fold lower than reported exposure with oral sirolimus. Systemic concentrations remained low and stable over 24 hours, with exposure consistent across age groups, treated lesion areas, disease severities, and administered doses. The substantially lower mean systemic exposure observed with QTORIN™ rapamycin compared with reported oral sirolimus exposure potentially supports a favorable systemic exposure profile.
In August 2026, Palvella completed the rolling submission of its New Drug Application (NDA) to the FDA for QTORIN™ rapamycin for the treatment of microcystic LMs.
Real-World Claims Analysis Identifies an Estimated 154,986 Diagnosed DSAP Patients in the U.S.
The poster, titled “Real world analysis of paid claims database reveals that disseminated superficial actinic porokeratosis (DSAP) is a large orphan disease,” presents findings from an eight-year analysis of U.S. paid claims data from Komodo Health, designed to estimate the number of patients diagnosed with DSAP in the U.S. and characterize their demographics, associated comorbidities, and treatment patterns.
The analysis identified an estimated 154,986 U.S. patients diagnosed with DSAP during 2018–2025. The methodology required at least two occurrences of ICD-10 diagnosis code L56.5 and adjustments for age-specific population capture rates. These findings represent the first real-world, claims-based characterization of the diagnosed DSAP population in the U.S. and highlight the substantial burden of a chronic, progressive disease for which no FDA-approved therapies currently exist.
Palvella’s second product candidate, QTORIN™ pitavastatin, is being developed for the treatment of DSAP, with a Phase 2 trial anticipated to commence in the fourth quarter of 2026.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular anomalies for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular anomalies, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from clinical trials, Palvella’s clinical development plans and related anticipated development milestones and anticipated timing of regulatory submissions, Palvella’s plans with respect to the timing of, and anticipated FDA review process for, the NDA for QTORIN™ rapamycin, Palvella’s plans to pursue Breakthrough Therapy Designation, Palvella’s plans to meet with regulatory authorities, Palvella’s expectations regarding the benefits of orphan drug designation and potential benefit of orphan drug exclusivity for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, Palvella’s cash, financial resources and expected runway, Palvella’s expectations regarding its programs, including QTORIN™ rapamycin and QTORIN™ pitavastatin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to make regulatory submissions on anticipated timelines; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin and QTORIN™ pitavastatin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; Palvella’s limited experience in commercial manufacturing; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO
Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Vice President, Investor Relations and Corporate Affairs
Palvella Therapeutics
marcy.nanus@palvellatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Palvella's Phase 3 SELVA study show for QTORIN rapamycin?
Among participants completing SELVA’s 24-week efficacy evaluation period, 95% improved on the primary investigator assessment of microcystic lymphatic malformations, including 86% rated “Much Improved” or “Very Much Improved.” All Week 24 exit-interview participants reported meaningful improvement in at least one symptom, most commonly bleeding/leaking and color.
How did systemic exposure to Palvella's QTORIN rapamycin compare with oral sirolimus?
In a 24-participant maximal-use substudy, mean systemic rapamycin exposure with QTORIN rapamycin was at least 40-fold lower than reported exposure with oral sirolimus. Concentrations remained low and stable over 24 hours. The comparison used published oral rapamycin pharmacokinetic data, which describe drug exposure in the body.
How did Palvella estimate the number of U.S. patients diagnosed with DSAP?
The analysis used Komodo Health U.S. paid claims data from 2018–2025, requiring at least two occurrences of diagnosis code L56.5 and adjustments for age-specific population capture rates. This method estimated 154,986 U.S. patients diagnosed with disseminated superficial actinic porokeratosis, or DSAP.